Abstract
Omalizumab is recently developed monoclonal anti-IgE antibody. Clinical trials have demonstrated its efficacy in patients with moderate-to-severe and severe or poorly controlled allergic asthma, in patients with seasonal and perennial allergic disease and in subjects with concomitant asthma and allergic rhinitis. Patients with more severe asthma appear to obtain the greatest benefit from omalizumab therapy. Omalizumab is well tolerated and has a good safety profile. Anti-inflammatory activity has been shown in both allergic asthma and allergic rhinitis [1,2]. Omalizumab is not a firstline therapy in asthmatic patients. FDA (Food and Drug Administration ) approved omalizumab use in June of 2003 for patients satisfying the following criteria (all must be present): 1- total IgE concentration in serum 30-700 klU L. 2- skin test positive for at least one perennial allergen; 3- specific IgE concentration positive for at least one perennial allergen (house dust mite, cat and dog); 4- asthma: moderate to severe persistent asthma; 5- age: > 12 years; 6- inadequate control despite inhaled corticosteroids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy
Volume: 7 Issue: 1
Author(s): I. Olcay
Affiliation:
Abstract: Omalizumab is recently developed monoclonal anti-IgE antibody. Clinical trials have demonstrated its efficacy in patients with moderate-to-severe and severe or poorly controlled allergic asthma, in patients with seasonal and perennial allergic disease and in subjects with concomitant asthma and allergic rhinitis. Patients with more severe asthma appear to obtain the greatest benefit from omalizumab therapy. Omalizumab is well tolerated and has a good safety profile. Anti-inflammatory activity has been shown in both allergic asthma and allergic rhinitis [1,2]. Omalizumab is not a firstline therapy in asthmatic patients. FDA (Food and Drug Administration ) approved omalizumab use in June of 2003 for patients satisfying the following criteria (all must be present): 1- total IgE concentration in serum 30-700 klU L. 2- skin test positive for at least one perennial allergen; 3- specific IgE concentration positive for at least one perennial allergen (house dust mite, cat and dog); 4- asthma: moderate to severe persistent asthma; 5- age: > 12 years; 6- inadequate control despite inhaled corticosteroids
Export Options
About this article
Cite this article as:
Olcay I., Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (1) . https://dx.doi.org/10.2174/187152308783769131
DOI https://dx.doi.org/10.2174/187152308783769131 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Longevity Depends on a Balance Between Proinflammatory and Anti-Inflammatory Factors: Use of Tcms and Natural Products
Current Drug Discovery Technologies Mast Cells: Pivotal Players in Cardiovascular Diseases
Current Cardiology Reviews Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Drug Delivery Letters A Comprehensive Literature Review of COPD-Related Fatigue
Current Respiratory Medicine Reviews Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy NF-κB in Anti-Inflammatory Activity of Probiotics: An Update
Current Immunology Reviews (Discontinued) Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Melatonin Could Be Beneficial in SARS-CoV-2 Therapy
The Natural Products Journal Medical Treatment of COPD Patients with Mild and Moderate Airflow Obstruction
Current Respiratory Medicine Reviews The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry Structure-Function Relationships and Clinical Applications of L-Asparaginases
Current Medicinal Chemistry The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered- Dose Inhaler in the Treatment of COVID-19 Patients
Recent Advances in Drug Delivery and Formulation Mast Cells in Abdominal Aortic Aneurysms
Current Vascular Pharmacology Determinants of an Adequate Inhaler Technique in Frail Elderly Patients
Current Respiratory Medicine Reviews 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry The Role of Vitamin D in Prevention and Treatment of Infection
Inflammation & Allergy - Drug Targets (Discontinued) Choosing Optimal Firstline Helicobacter pylori Therapy: a View from a Region with High Rates of Antibiotic Resistance
Current Pharmaceutical Design